Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect study of QLS1410 in healthy Chinese adults
NCT07358858Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Feb 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of QLS1410 in hypertension (HTN) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Area Under the Curve from Time Zero to Infinity, Area Under the Curve from Time Zero to Last Quantifiable Concentration and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
QLS1410
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07358858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07358858.